DBV Technologies peanut allergy drug fails key study
October 20, 2017 at 16:49 PM EDT
Oct 20 (Reuters) - Drug developer DBV Technologies SA said on Friday its peanut allergy treatment did not meet the main goal in a highly anticipated late-stage study.